SuspendedPhase 2

Montelukast for Prevention & Treatment of OHSS

Stopped: no fund

Egypt20 participantsStarted 2018-12-05

Plain-language summary

montelukast \& dydrgesteron will be given to cases with suspected or proven ovarian hyperstimulation in one group in comparison with dydrogesteron alone in the other group.

Who can participate

Age range20 Years – 37 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * PCOS high responders high numbers of ovum retrieved Exclusion Criteria: * hypersensitivity to any drug components phenylketonuria patients depression liver dysfunction

What they're measuring

Number of Participants who develop ovarian hyperstimulation syndrome

Timeframe: 0-14 days

Trial details

NCT IDNCT03794037

SponsorBenha University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12

View on ClinicalTrials.gov More Ovarian Hyperstimulation Syndrome trials